10月19日 - ** 由人工智能巨头英伟达（NVDA.O）支持的药物研发公司 Iambic Therapeutics（IAM.O）的股价在周一的第三个交易日一度暴跌41%，至14.10美元
** IAM于周四以16.15美元开盘，此前该公司 (link) 以16美元的价格完成了1.5亿美元的首次公开募股（IPO），该价格处于发行区间的中点 (link)
** 该股周五收盘上涨约26%，报23.81美元，盘中一度触及25美元高点
** 尽管市场波动与债券收益率飙升共同抑制了投资者对新股的兴趣 (link)，但生物科技公司的新股发行 (link) 仍在持续进行
** Iambic正推进其利用人工智能平台开发的用于治疗实体瘤的候选药物管线。该公司已与包括艾伯维（AbbVie） ABBV.N 和武田制药（Takeda Pharmaceutical）在内的顶级制药公司建立了合作伙伴关系 4502.T
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.